• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Orexo

22.70 SEK-5.22 %10.7. klo 10.29
Less than 1K followers

ORX

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-5.22 %
+15.23 %
+9.40 %
-34.30 %
-24.58 %
+14.65 %
+53.38 %
-40.29 %
-74.76 %

Orexo is a Swedish pharmaceutical company that develops improved medicines based on proprietary formulation technologies and with a focus on meeting major medical needs. In the US market, Orexo commercializes treatments for patients suffering from opioid addiction. Products targeting other therapeutic areas are developed and commercialized worldwide through partners.

Read more
Market cap
843.46M SEK
Turnover
207.97K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
16.7.
2026

Interim report Q2'26

22.10.
2026

Interim report Q3'26

4.2.
2027

Annual report '26

Press release09.06.2026 klo 09.00

Orexo appoints Raheleh Nassaji as SVP Business Development, strengthening its focus on new partnerships

Orexo
Press release19.05.2026 klo 12.38

DNB Carnegie Access: Orexo: Promising early-stage data

Orexo
Press release19.05.2026 klo 09.00

Orexo announces positive outcome from an in-vivo study of OX390

Orexo

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release07.05.2026 klo 18.00

Report from Orexo AB’s annual general meeting May 7 2026

Orexo
Press release29.04.2026 klo 09.40

DNB Carnegie Access: Orexo: Better visibility, few near-term catalysts – Q1 review

Orexo
Regulatory press release28.04.2026 klo 08.00

Orexo Q1 2026 Interim Report

Orexo
Press release21.04.2026 klo 11.00

Invitation to presentation of Orexo´s Q1 2026 Interim Report

Orexo
Regulatory press release31.03.2026 klo 18.30

Number of shares and votes in Orexo

Orexo
Press release30.03.2026 klo 13.00

Notice of Annual General Meeting of Orexo

Orexo
Regulatory press release27.03.2026 klo 11.00

Orexo publishes Annual Report for 2025

Orexo
Press release24.03.2026 klo 20.53

DNB Carnegie Access: Orexo: Key takeaways from R&D Day

Orexo
Press release24.03.2026 klo 08.30

Orexo R&D Day - Building global leadership in amorphous drug delivery

Orexo
Press release06.03.2026 klo 11.00

Invitation & Agenda: Orexo R&D Day on March 24

Orexo
Press release06.03.2026 klo 10.43

DNB Carnegie Access: Orexo: Management changes no major surprise

Orexo
Press release06.03.2026 klo 09.00

Orexo changes the organizational structure and management team to increase focus on development of new products

Orexo
Press release04.03.2026 klo 09.00

Orexo calls for early redemption of its outstanding senior secured social bonds 2024/2028

Orexo
Regulatory press release19.02.2026 klo 18.30

Orexo: Conversion of Class C shares into ordinary shares and conveyance of ordinary shares within the framework of long-term performance-based incentive programs

Orexo
Press release06.02.2026 klo 11.53

DNB Carnegie Access: Orexo: Busy quarter paves the way for a fresh start – Q4 review

Orexo
Regulatory press release05.02.2026 klo 08.00

Orexo Interim Report Q4 2025, incl. Full Year Report

Orexo
Press release04.02.2026 klo 10.30

Save the date: Orexo to host R&D Day on March 24

Orexo